Mild renal impairment and the efficacy and safety of liraglutide

Endocrine Practice

Volumn 17, Issue 3, 2011, Pages 345-355

  Davidson, Jaime A ^a   Brett, Jason ^b   Falahati, Ali ^c   Scott, David ^d,e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NOVO NORDISK INC   (United States)

^c NOVO NORDISK A S   (Denmark)

^d Clinical Research Development Associates LLC   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 79959692519     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP10215.OR     Document Type: Article

References (35)

1. American Diabetes Association. Standards of medical care in diabetes-2010 [Erratum in Diabetes Care. 2010;33:692]. Diabetes Care. 2010;33(Suppl 1):S11-S61.
2. Amaryl [glimepiride tablets] [prescribing information]. Bridgewater, NJ: Sanofi-aventis US LLC; 2009. Available at: Http://products.sanofi-aventis.us/ amaryl/amaryl.pdf.
3. Glucotrol XL [glipizide extended release tablets] [prescribing information]. New York, NY: Pfizer; 2009. Available at: Http://www.pfizer.com/ files/products/uspi-glucotrol-xl.pdf.
4. Precose [acarbose tablets] [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2011. Available at: Http://www.univgraph.com/Bayer/ inserts/Precose.pdf.
5. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab. 2008;10:811-823.
6. Mühlhauser I, Toth G, Sawicki PT, Berger M. Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care. 1991;14:344-346.
7. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17:365-370. (Pubitemid 39422090)
8. Lantus [insulin glargine (rDNA origin) injection] [prescribing information]. Bridgewater, NJ: Sanofi-aventis US LLC; 2007. Available at: Http://products.sanofi-aventis.us/lantus/lantus.html.
9. Levemir [insulin detemir (rDNA origin) injecion] [prescribing information]. Princeton, NJ: Novo Nordisk Inc; 2009. Available at: Http://www.levemir-us.com/downloads/levemir-prescribing-information.pdf.
10. Januvia [sitagliptin tablets] [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; 2010. Available at: Http://www.merck.com/ product/usa/pi-circulars/j/januvia/januvia-pi.pdf.
11. Onglyza [saxagliptin tablets] [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2011. Available at: Http://packageinserts.bms.com/pi/pi- onglyza.pdf.
12. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
13. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62:173-181. (Pubitemid 40674548)
14. Ruiz-Grande C, Alarcón C, Alcántara A, et al. Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res. 1993;25:612-616. (Pubitemid 24001825)
15. Byetta [exenatide injection] [prescribing information]. San Diego, CA: Amylin Pharmaceuticals; 2010. Available at: Http://pi.lilly.com/us/byetta-pi. pdf.
16. Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatide-associated ischemic renal failure. Diabetes Care. 2009;32:e22-e23.
17. Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
18. Marre M, Shaw J, Brändle M, et al; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-278.
19. Nauck M, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
20. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224-1230.
21. Helleberg H, Malam-Erjefalt M., Bjornsdottir I, et al. Metabolism and excretion of [Pal-3H]-liraglutide in human healthy subjects. 2008;57(Suppl 1):A581 [Abstract 2107-PO]
22. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68: 898-905.
23. Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
24. Russell-Jones D, Vaag A, Schmitz O, et al; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia. 2009;52:2046-2055.
25. Sarnak MJ, Levey AS, Schoolwerth AC, et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42:1050-1065. (Pubitemid 37413751)
26. Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30:1049-1055. (Pubitemid 46684623)
27. Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther. 2011;28:213-226.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
29. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470. (Pubitemid 29135798)
30. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol. 2002;13:2140-2144. (Pubitemid 34790792)
31. Harmoinen A, Lehtimäki T, Korpela M, Turjanmaa V, Saha H. Diagnostic accuracies of plasma creatinine, cystatin C, and glomerular filtration rate calculated by the Cockcroft-Gault and Levey (MDRD) formulas. Clin Chem. 2003;49:1223-1225. (Pubitemid 36751123)
32. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
33. Roberts GW, Ibsen PM, Schiøler CT. Modified diet in renal disease method overestimates renal function in selected elderly patients. Age Ageing. 2009;38:698-703.
34. Victoza Prescribing Information (US) 2010. Available at: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022341lbl.pdf.
35. Victoza Prescribing Information (EU) 2010. Available at: Http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001026/WC500050017.pdf.